On August 4, 2025, Arbutus Biopharma announced the resignation of director Anuj Hasija and appointed Dr. Roger Sawhney to the Board, along with an initial stock option for 157,600 shares. Additionally, updates on ongoing patent litigation against Moderna and Pfizer/BioNTech were provided, with significant hearings expected in 2026.